HCW Biologics Inc. (HCWB): Price and Financial Metrics


HCW Biologics Inc. (HCWB): $2.06

0.03 (+1.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HCWB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HCWB Stock Price Chart Interactive Chart >

Price chart for HCWB

HCWB Price/Volume Stats

Current price $2.06 52-week high $7.78
Prev. close $2.03 52-week low $1.89
Day low $1.91 Volume 11,800
Day high $2.40 Avg. volume 54,379
50-day MA $2.41 Dividend yield N/A
200-day MA $2.76 Market Cap 73.74M

HCW Biologics Inc. (HCWB) Company Bio


HCW Biologics Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation and age-related diseases. The company is involved in developing HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. It is also developing HCW9218 as an injectable immunotherapeutic for patients with pancreatic, breast, ovarian, colorectal, and prostate cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata. The company was incorporated in 2018 and is headquartered in Miramar, Florida.


HCWB Latest News Stream


Event/Time News Detail
Loading, please wait...

HCWB Latest Social Stream


Loading social stream, please wait...

View Full HCWB Social Stream

Latest HCWB News From Around the Web

Below are the latest news stories about HCW Biologics Inc that investors may wish to consider to help them evaluate HCWB as an investment opportunity.

Masonic Cancer Center To Evaluate HCW Biologics'' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc''s (NASDAQ: HCWB ) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex Full story available on Benzinga.com

Benzinga | January 24, 2022

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in Phase 1 trial in patients with advanced solid tumors with progressive disease after prior chemotherapies. HCW9218 is an injectable, bifunctional fusion protein complex designed to drive anti-tumor activity by activating desired immune responses to attack cancer cells while simultaneously blocking unwanted immunosuppressive activities. Hing C. Wong, Ph

Yahoo | January 24, 2022

Masonic Cancer Center at the University of Minnesota Receives FDA Clearance to Proceed with Phase 1 Clinical Trial in Solid Tumors for HCW9218, HCW Biologics’ Novel Bifunctional Fusion Protein

UM cleared to proceed with clinical trial to evaluate HCW9218 in various advanced solid tumors, such as breast, ovarian, prostate, and colorectal cancersMIRAMAR, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that the Masonic Cancer Center, University of Min

Yahoo | January 24, 2022

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc (NASDAQ: HCWB ) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced Full story available on Benzinga.com

Benzinga | January 20, 2022

Aptorum, HCW Biologics lead healthcare gainers; Star Equity, G Medical among losers

Aptorum APM +35%. HCW Biologics (HCWB) +18%. Star Equity STRR -30%. G Medical Innovations GMVD -21%.

Seeking Alpha | January 20, 2022

Read More 'HCWB' Stories Here

HCWB Price Returns

1-mo -12.71%
3-mo -7.21%
6-mo -28.72%
1-year N/A
3-year N/A
5-year N/A
YTD -11.21%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6444 seconds.